Revenue N/A
EBITDA N/A
Income -$8.31
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E 0.00
Forward P/E N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT 0.43
PEG N/A
Price/Sales 786.89
P/FCF N/A
Price/Book 3.46
Book/Share 0.02
Cash/Share N/A
FCF yield -37.07%
Employees 0
RPE N/A
Volume 8.383M / 36.438k
Relative vol. 230.07 ×
EPS N/A
EPS Q/Q -99.00%
Est. EPS Q/Q 384.00%
Profit margin N/A
Oper. margin -25,071.23%
Gross margin N/A
EBIT margin -11,424.66%
EBITDA margin -28,224.66%
Ret. on assets -36.48%
Ret. on equity -50.31%
ROIC -28.96%
ROCE -52.53%
Volatility 24.69%
Beta 0.00
RSI 40.18
Range $0.24 – $0.24
52 weeks $0.06 – $0.24
SMA 50 $0 +70.83%
SMA 200 $0 +70.83%
1 year target $3 +1,150.00%
Mean Recomm. 1.50
Shares outst. 7.376M
Shares float 0.000 0.00%
Short % of float 2.44%
Short ratio 0.53

Recent PolarityTE Inc news

Friday, 6 May 2022
 
morningstar
PolarityTE to Report Q1 2021 Financial Results on May 16, 2022
Wednesday, 13 April 2022
 
yahoo
Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers - Yahoo Finance
Tuesday, 12 April 2022
 
yahoo
BioMed Stocks On the Move: Nova Mentis, PolarityTE, Biodesix and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, New Drugs for Cancers, Glaucoma, and Autism, and Diagnostics. - Yahoo Finance
Wednesday, 30 March 2022
 
nasdaq
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
Wednesday, 16 March 2022
 
markets.businessinsider
PolarityTE Announces $5.0 Million Registered Direct Offering
Monday, 22 November 2021
 
duckduckgo
UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Friday, 19 November 2021
 
yahoo
PTE FINAL DEADLINE TUESDAY: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE
stockhouse
DEADLINE TUESDAY REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Tuesday, 16 November 2021
 
globenewswire
ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE
Wednesday, 10 November 2021
 
businesswire
POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm
Thursday, 28 October 2021
 
morningstar
PolarityTE to Report Third Quarter Financial Results on November 10, 2021
Tuesday, 19 October 2021
 
yahoo
ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors to Secure Counsel Before Important November 23 Deadline in Securities Class Action - PTE
Saturday, 9 October 2021
 
duckduckgo
ROSEN, A LEADING LAW FIRM, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
Monday, 4 October 2021
 
duckduckgo
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against PolarityTE, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Monday, 27 September 2021
 
duckduckgo
POLARITYTE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against PolarityTE, Inc. and Encourages Investors to Contact the Firm
Wednesday, 28 July 2021
 
morningstar
SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial
Monday, 26 July 2021
 
businesswire
PolarityTE Submits Investigational New Drug Application for SkinTE® in Chronic Cutaneous Ulcers
Friday, 16 July 2021
 
businesswire
PolarityTE Issues Statement About Potential Ticker Symbol Confusion
Monday, 12 July 2021
 
yahoo
PolarityTE Receives Notice of Allowance for Chinese Patent
Thursday, 13 May 2021
 
yahoo
PolarityTE Reports First Quarter Results and Provides Business Update
Monday, 10 May 2021
 
yahoo
PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint
Monday, 3 May 2021
 
yahoo
PolarityTE to Report First Quarter Financial Results on May 13, 2021
Tuesday, 30 March 2021
 
yahoo
PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results
Wednesday, 10 March 2021
 
yahoo
PolarityTE to Report Fiscal Year 2020 Financial Results on March 30, 2021
Friday, 22 January 2021
 
apnews
PolarityTE, Inc. Announces Exercise of Warrants for Gross Proceeds of $7.67 Million
Thursday, 21 January 2021
 
yahoo
PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial
Thursday, 14 January 2021
 
yahoo
PolarityTE Announces Closing of $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Tuesday, 12 January 2021
 
yahoo
PolarityTE Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Monday, 11 January 2021
 
yahoo
PolarityTE Announces Formation of Strategic Review Committee
Monday, 30 November 2020
 
yahoo
PolarityTE Receives Allowance for First U.S. Patent
Tuesday, 24 November 2020
 
yahoo
PolarityTE Announces Dismissal of Securities Class Action Complaint with Prejudice
Monday, 21 September 2020
 
yahoo
PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds
Wednesday, 16 September 2020
 
yahoo
SkinTE™ Health Economics—DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure
Monday, 14 September 2020
 
yahoo
PolarityTE Expects Third Quarter Revenue to Meet or Exceed High-End of Guidance
Thursday, 10 September 2020
 
yahoo
PolarityTE to Present at H.C. Wainwright 22nd Annual Global Investment Conference and Cantor Virtual Global Healthcare Conference
Wednesday, 29 July 2020
 
yahoo
PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020
Friday, 24 July 2020
 
businesswire
PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE™ Diabetic Foot Ulcer Trial
Wednesday, 10 June 2020
 
zacks
Rising P/E: An Overlooked Trick to Pick 5 Winning Stocks
Tuesday, 21 April 2020
 
yahoo
PolarityTE Provides Corporate Update Related to COVID-19 and Announces Preliminary First Quarter Results
Wednesday, 8 April 2020
 
tylerpaper
PolarityTE Announces Conclusion of SEC Investigation
Monday, 6 April 2020
 
yahoo
PolarityTE Announces the Addition of Audit Executive Chris Nolet to Board of Directors
Sunday, 15 March 2020
 
yahoo
Earnings Release: Here's Why Analysts Cut Their PolarityTE, Inc. Price Target To US$10.17
Thursday, 12 March 2020
 
businesswire
PolarityTE Reports Fiscal Year 2019 Financial Results
Thursday, 5 March 2020
 
yahoo
PolarityTE to Attend the Oppenheimer 30th Annual Healthcare Conference
Wednesday, 12 February 2020
 
businesswire
PolarityTE Announces Pricing of Public Offering of Common Stock and Warrants
Thursday, 19 December 2019
 
yahoo
Hedge Funds Are Crazy About PolarityTE, Inc.
Wednesday, 18 December 2019
 
marketscreener
PolarityTE to Participate in Corporate Access Event in San Francisco, January 13-15, 2020
8-K 18 Aug 2023 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
8-K 15 Aug 2023 Completion of Acquisition or Disposition of Assets; Financial Statements and Exhibits
8-K 1 Aug 2023 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
8-K 7 Jul 2023 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K 7 Jun 2023 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K 7 Jun 2023 Entry into a Material Definitive Agreement; Bankruptcy or Receivership; Regulation FD Disclosure; Financial...
10-Q 12 May 2023 Quarterly report
8-K 26 Apr 2023 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10-K 27 Mar 2023 Yearly report
8-K 20 Mar 2023 Other Events
8-K 26 Jan 2023 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
Insider
Trans.
Transaction
Price per share Total value
Chris Nolet Director Option 12 Jan 2023 $0.79 $28,833
Peter A Cohen Director Sale 17 Aug 2022 $1.28 $10,950
Peter A Cohen Director Sale 16 Aug 2022 $1.33 $20,091
David B Seaburg Director Sale 19 Oct 2021 $0.55 $17,070
David B Seaburg Director Option 1 Sep 2021 $17.67 $565,599
Richard Hague Chf. Exec. Off. and Pres. Sale 9 Aug 2021 $0.83 $8,473
David B Seaburg Director Sale 16 Jul 2021 $0.71 $22,033
Richard Hague Chf. Exec. Off. and Pres. Sale 16 Jul 2021 $0.71 $8,946
Richard Hague Chf. Exec. Off. and Pres. Sale 29 Jun 2021 $1.02 $6,437
Peter A Cohen Director Buy 18 May 2021 $0.98 $259,700
David B Seaburg Director Sale 19 Apr 2021 $0.87 $26,997
Q2 2019
8 August 2019
Management on Q2 2019 Results - Earnings Call Transcript
Q1 2019
10 May 2019
CEO Denver Lough on Q1 2019 Results - Earnings Call Transcript

7,884 people own PolarityTE Inc on Robinhood

Powered by Robintrack.

Overall analyst rating

Price target

Current $0.24
Average $3.00
Low $3 High $3

Dividends

Ex-dividend date N/A Frequency Irregular Annual dividend +0.00%
Next dividend N/A Dividend yield 0.00% Growth period N/A
Last dividend date Yield 3 years 0.00% Growth 3 years +0.00%
Last dividend Yield 5 years 0.00% Growth 5 years +0.00%

PolarityTE Inc dividend history

PolarityTE Inc executives

Insider Age Since Compensation
Richard Hague (61) Pres and CEO 61 $649,256
Cameron J. Hoyler (37) Gen. Counsel, Sec., Exec. VP of Corp. Devel., and Strategy 37 $623,192
Daniel Gasiorowski
Wladyslaw Zmuda 2020
Michal Zadlo 2020
Beata Sobocinska 2020
Kamila Krawiec 2018
Michal Herominski 2018
Patryk Gall 2020
Emil Cybulski 2017
Pawel Cieslik 2018
Maria Biernacik-Bankowska 2018
Agnieszka Kosno
Zbigniew Stawinoga 2018
Rafal Markiewicz 2018
Mark E. Lehman J.D.
Ryan Mathis M.D.
Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. (58) Sr. VP of Corp. Devel. and Pres of Contract Services 58
Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS (72) Chief Clinical Officer and Member of Clinical Advisory Board 72
Alain Adam
Angela Ziegler
Rich Haerle
Nikolai Sopko
Jacob Alexander Patterson (42) Chief Financial Officer 42
Company Market cap P/E EV/EBITDA P/S P/B P/FCF Change
$57.44M 0.00 N/A 786.89 3.46 N/A -0.82%
$291.20M 0.00 N/A 14.87 2.93 N/A +0.18%
$127.55M N/A N/A 269.35 1.45 N/A +2.81%

polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients'​ own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™

  • Health Care > Biotechnology
  • PolarityTE Inc, 1960 South 4250 West, Salt Lake City 84104, United States
  • 800 560 3983
  • Investor relations

Dividends

Ex-dividend date N/A Frequency Irregular Annual dividend +0.00%
Next dividend N/A Dividend yield 0.00% Growth period N/A
Last dividend date Yield 3 years 0.00% Growth 3 years +0.00%
Last dividend Yield 5 years 0.00% Growth 5 years +0.00%

PolarityTE Inc dividend history

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

(in millions USD) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Current assets
Cash $6.394 $11.446 $16.094 $20.518
Short term investments
Net receivables
Inventory
Total current assets $8.927 $13.255 $18.489 $22.897
Long term investments
Property, plant & equipment $8.211 $8.681 $2.745 $4.224
Goodwill & intangible assets
Total noncurrent assets $9.122 $9.592 $3.656 $5.134
Total investments
Total assets $18.049 $22.847 $22.145 $28.031
Current liabilities
Accounts payable $1.714 $1.38 $1.895 $1.944
Deferred revenue
Short long term debt
Total current liabilities $2.172 $2.067 $2.799 $3.512
Long term debt $2.495 $2.673 $0.052 $0.063
Total noncurrent liabilities $3.456 $4.162 $2.403 $4.473
Total debt $2.495 $2.673 $0.052 $0.063
Total liabilities $5.628 $6.229 $5.202 $7.985
Stockholders' equity
Retained earnings -$520.474 -$516.231 -$515.637 -$512.237
Other stockholder equity
Total stockholder equity $12.421 $16.618 $16.943 $20.046
(in millions USD) 2022 2021 2020
Current assets
Cash $11.446 $19.375 $25.522
Short term investments
Net receivables $0.978 $3.819
Inventory $0.883
Total current assets $13.255 $22.389 $31.216
Long term investments
Property, plant & equipment $8.681 $8.069 $13.002
Goodwill & intangible assets $0.82
Total noncurrent assets $9.592 $8.789 $14.294
Total investments
Total assets $22.847 $31.178 $45.51
Current liabilities
Accounts payable $1.38 $3.115 $4.148
Deferred revenue $0.074 $0.168
Short long term debt $2.059
Total current liabilities $2.067 $4.709 $8.481
Long term debt $2.673 $0.043 $2.993
Total noncurrent liabilities $4.162 $7.225 $9.691
Total debt $2.673 $0.043 $5.052
Total liabilities $6.229 $11.934 $18.172
Stockholders' equity
Retained earnings -$516.231 -$508.398 -$478.211
Other stockholder equity
Total stockholder equity $16.618 $19.244 $27.338

Income statement

(in millions USD) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Revenue
Total revenue $0.073
Cost of revenue $0.125
Gross profit -$0.052
Operating activities
Research & development $2.282 $2.559 $2.551 $3.078
Selling, general & administrative $2.464 $2.571 $2.685 $3.562
Total operating expenses $4.802 $1.365 $5.405 $6.678
Operating income -$4.802 -$1.365 -$5.405 -$6.73
Income from continuing operations
EBIT -$4.274 -$0.616 -$3.396 -$0.054
Income tax expense
Interest expense -$0.031 -$0.022 $0.004 $0.014
Net income
Net income -$4.243 -$0.594 -$3.4 -$0.068
Income (for common shares) -$4.243 -$0.594 -$3.4 -$0.068
(in millions USD) 2022 2021 2020
Revenue
Total revenue $0.814 $9.404 $10.126
Cost of revenue $0.616 $4.316 $4.424
Gross profit $0.198 $5.088 $5.702
Operating activities
Research & development $11.048 $14.182 $11.532
Selling, general & administrative $15.027 $23.284 $36.276
Total operating expenses $22.571 $38.774 $51.642
Operating income -$22.373 -$33.686 -$45.94
Income from continuing operations
EBIT -$7.822 -$30.06 -$42.672
Income tax expense
Interest expense $0.011 $0.127 $0.182
Net income
Net income -$7.833 -$30.187 -$42.854
Income (for common shares) -$7.833 -$30.187 -$42.854
(in millions USD) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Net income -$4.243 -$0.594 -$3.4 -$0.068
Operating activities
Depreciation $0.148 $0.276 $0.373 $0.403
Business acquisitions & disposals $2.327
Stock-based compensation $0.046 $0.268 $0.297 $0.53
Total cash flows from operations -$5.08 -$4.298 -$4.032 -$8.226
Investing activities
Capital expenditures $0.1 $0.058 $0.024 $0.158
Investments
Total cash flows from investing $0.1 $0.058 $0.024 $2.485
Financing activities
Dividends paid
Sale and purchase of stock $0.001 $7.825
Net borrowings -$0.072 -$0.409 -$0.416 -$0.413
Total cash flows from financing -$0.072 -$0.408 -$0.416 $7.361
Effect of exchange rate
Change in cash and equivalents -$5.052 -$4.648 -$4.424 $1.62
(in millions USD) 2022 2021 2020
Net income -$7.833 -$30.187 -$42.854
Operating activities
Depreciation $1.507 $2.842 $3.263
Business acquisitions & disposals $2.327
Stock-based compensation $1.857 $5.381 $7.258
Total cash flows from operations -$22.597 -$22.63 -$37.754
Investing activities
Capital expenditures $0.216 -$0.096 -$1.339
Investments $18.972
Total cash flows from investing $2.543 -$0.096 $17.633
Financing activities
Dividends paid
Sale and purchase of stock $7.826 $16.613 $33.134
Net borrowings -$0.337 -$0.581 $2.446
Total cash flows from financing $12.125 $16.579 $35.425
Effect of exchange rate
Change in cash and equivalents -$7.929 -$6.147 $15.304

Recent institutional transactions

Quarter Shareholder Change
Shares owned
Shares
Value (in thousands USD)
2023 Q4 Fsa Wealth Management
Opened
8 $0
2023 Q3 Strategic Investment Solutions, il
+6,200.00%
2,520 $191
2022 Q3 Millennium Management
-42.57%
20,548 $18
2022 Q3 American Portfolios Advisors
Opened
1 $1
2022 Q2 Citadel Advisors
Sold out
23,792 $35
2022 Q1 American Portfolios Advisors
Sold out
3 $1

Institutional shareholders

Shareholder Stake
Shares owned
Shares
Value (in thousands USD)
Citadel Advisors 0.32% 23,792
Millennium Management 0.28% 20,548
Strategic Investment Solutions, il 0.03% 2,520
Game Plan Advisors 0.00% 40
Fsa Wealth Management 0.00% 8
American Portfolios Advisors 0.00% 4